Juvenile dermatomyositis: Immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use

Pediatric Dermatology

Volumn 28, Issue 4, 2011, Pages 357-367

  Chiu, Yvonne E ^a   Co, Dominic O ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; INFLIXIMAB; ISOTRETINOIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MI 2 AUTOANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYOSITIS ASSOCIATED AUTOANTIBODY; MYOSITIS SPECIFIC AUTOANTIBODY; OFATUMUMAB; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; SIGNAL RECOGNITION PARTICLE AUTOANTIBODY; STEROID; SYNTHETASE AUTOANTIBODY; TACROLIMUS; TOSITUMOMAB; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA AUTOANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; BRONCHITIS; CD4+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DENDRITIC CELL; DERMATOMYOSITIS; DISEASE DURATION; DRUG FEVER; DRUG INDUCED HEADACHE; ENVIRONMENTAL FACTOR; ERYTHEMA; FLUSHING; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; JUVENILE DERMATOMYOSITIS; MICROCHIMERISM; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; T LYMPHOCYTE; THROAT IRRITATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

AMINO ACYL-TRNA SYNTHETASES; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; B-LYMPHOCYTES; CHILD; CHIMERISM; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DERMATOMYOSITIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MICE; SIGNAL RECOGNITION PARTICLE; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 79960803762     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2011.01501.x     Document Type: Review

References (71)

1. Mendez EP, Lipton R, Ramsey-Goldman R, et al., US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49: 300.
2. Dugan EM, Huber AM, Miller FW, et al., Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009; 15: 1.
3. Gerami P, Walling HW, Lewis J, et al., A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007; 157: 637-644. (Pubitemid 47389863)
4. Huber AM,. Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment. Paediatr Drugs 2009; 11: 361.
5. Wedderburn LR, Rider LG,. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 2009; 23: 665.
6. Pestronk A, Schmidt RE, Choksi R,. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 2010; 42: 53-61.
7. Greenberg SA,. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69: 2008-2019. (Pubitemid 350145093)
8. Karpati G, Pouliot Y, Carpenter S,. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72.
9. Lõpez De Padilla CM, Vallejo AN, Lacomis D, et al., Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009; 60: 1160-1172.
10. Caproni M, Torchia D, Cardinali C, et al., Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 2004; 151: 784-791. (Pubitemid 39482111)
11. Fasth AER, Dastmalchi M, Rahbar A, et al., T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009; 183: 4792-4799.
12. Ishii W, Matsuda M, Shimojima Y, et al., Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008; 47: 1593-1599.
13. Aleksza M, Szegedi A, Antal-Szalmás P, et al., Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis 2005; 64: 1485-1489. (Pubitemid 41623862)
14. Bilgic H, Ytterberg SR, Amin S, et al., Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436-3446.
15. Chevrel G, Page G, Granet C, et al., Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003; 137: 125-133. (Pubitemid 36351574)
16. Sakaguchi S, Miyara M, Costantino CM, et al., FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
17. Waschbisch A, Schwab N, Ruck T, et al., FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 2010; 225: 137-142.
18. Allenbach Y, Solly S, Grégoire S, et al., Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol 2009; 174: 989-998.
19. de Padilla CML, Reed AM,. Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2008; 20: 669-674.
20. Gilliet M, Cao W, Liu Y-J,. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8: 594-606.
21. Swiecki M, Colonna M,. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010; 234: 142-162.
22. Lõpez de Padilla CM, Vallejo AN, McNallan KT, et al., Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007; 56: 1658-1668. (Pubitemid 46764095)
23. Shrestha S, Wershil B, Sarwark JF, et al., Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 2010; 62: 2813-2822.
24. Baechler EC, Bauer JW, Slattery CA, et al., An interferon aignature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13: 59-68. (Pubitemid 46786834)
25. Niewold TB, Kariuki SN, Morgan GA, et al., Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009; 60: 1815-1824.
26. Salajegheh M, Kong SW, Pinkus JL, et al., Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67: 53-63.
27. Ishida T, Matsumoto Y, Ohashi M, et al., Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis. J Dermatol 1993; 20: 30-34. (Pubitemid 23138790)
28. Kikuchi Y, Koarada S, Tada Y, et al., Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis 2001; 60: 1137-1140. (Pubitemid 33096078)
29. Artlett CM, Ramos R, Jiminez SA, et al., Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 2000; 356: 2155-2156. (Pubitemid 32047955)
30. Reed AM, Picornell YJ, Harwood A, et al., Chimerism in children with juvenile dermatomyositis. Lancet 2000; 356: 2156-2157. (Pubitemid 32047956)
31. Artlett CM, Miller FW, Rider LG,. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 1279-1284.
32. Gunawardena H, Betteridge ZE, McHugh NJ,. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48: 607.
33. Love LA, Leff RL, Fraser DD, et al., A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360.
34. Brouwer R, Hengstman GJ, Vree Egberts W, et al., Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60: 116.
35. Hengstman GJ, Brouwer R, Egberts WT, et al., Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002; 249: 69.
36. Rider LG, Miller FW, Targoff IN, et al., A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37: 1534.
37. Feldman BM, Reichlin M, Laxer RM, et al., Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996; 23: 1794.
38. Wedderburn LR, McHugh NJ, Chinoy H, et al., HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46: 1786.
39. Zhang Y, LeRoy G, Seelig HP, et al., The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998; 95: 279.
40. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al., Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65: 1635.
41. Miller T, Al-Lozi MT, Lopate G, et al., Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73: 420.
42. Rouster-Stevens KA, Pachman LM,. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008; 35: 927.
43. Targoff IN, Trieu EP, Levy-Neto M, et al., Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis. Abstract. Arthritis Rheum 2006; 54: S518.
44. Dupont S, Mamidi A, Cordenonsi M, et al., FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136: 123.
45. Fujikawa K, Kawakami A, Kaji K, et al., Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 2009; 38: 263.
46. Kaji K, Fujimoto M, Hasegawa M, et al., Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46: 25.
47. Targoff IN, Mamyrova G, Trieu EP, et al., A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682.
48. Trallero-Araguas E, Labrador-Horrillo M, Selva-O'Callaghan A, et al., Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89: 47.
49. Hoshino K, Muro Y, Sugiura K, et al., Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726.
50. Gunawardena H, Wedderburn LR, North J, et al., Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47: 324.
51. Oddis CV, Fertig N, Goel A, et al., Clinical and serological characterisation of the anti-MJ antibody in childhood myositis. Abstract. Arthritis Rheum 1997; 40 (Suppl): S139.
52. Targoff IN, Trieu EP, Levy-Neto M, et al., Sera with autoantibodies to the MJ antigen react with NXP2. Abstract. Arthritis Rheum 2007; 56: S787.
53. Gunawardena H, Wedderburn LR, Chinoy H, et al., Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807.
54. Sato S, Hoshino K, Satoh T, et al., RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193.
55. Kang EH, Nakashima R, Mimori T, et al., Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11:223.
56. van Meerten T, Hagenbeek A,. CD20-targeted therapy: the next generation of antibodies. SeminHematol 2010; 47: 199.
57. Liossis SN, Sfikakis PP,. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008; 127: 280.
58. Levine TD,. A pilot study of rituximab therapy for refractory dermatomyositis. Arthritis Rheum 2002; 46: S488.
59. Chung L, Genovese MC, Fiorentino DF,. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143: 763.
60. Levine TD,. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601.
61. Endo LM, Theos A, Atkinson TP,. Use of rituximab in refractory juvenile dermatomyositis. Abstract. Arthritis Rheum 2005; 52: S288.
62. Cooper MA, Willingham DL, Brown DE, et al., Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56: 3107.
63. Dinh HV, McCormack C, Hall S, et al., Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007; 56: 148.
64. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, et al., Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009; 2: 6609.
65. Holzer U, van Royen-Kerkhof A, van der Torre P, et al., Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010; 39: 88.
66. van Vollenhoven RF, Emery P, Bingham CO 3rd, et al., Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37: 558.
67. Rituxan [Prescribing Information]. South San Francisco, CA: Genentech Inc., 2010.
68. Lee YH, Bae SC, Song GG,. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2010; May 16 [Epub ahead of print].
69. Salliot C, Dougados M, Gossec L,. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25.
70. Gea-Banacloche JC,. Rituximab-associated infections. Semin Hematol 2010; 47: 187.
71. Carson KR, Evens AM, Richey EA, et al., Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834.